Roper posted 4Q results with 10% total revenue growth and 4% organic growth, the latter coming in below expectations due to government shutdown impacts on Deltek license timing, though recurring subscription momentum and bookings remained strong, William Blair tells investors in a research note. The selloff appears overdone, and a solid 2026 outlook, a robust M&A pipeline with significant dry powder, and attractive valuation support a positive long-term view and an Outperform rating, the firm says.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROP:
- Oppenheimer downgrades Roper on organic growth challenges
- Roper Technologies downgraded to Perform from Outperform at Oppenheimer
- Roper Technologies price target lowered to $550 from $650 at Truist
- Midday Fly By: CMS proposal sinks insurers, UnitedHealth reports mixed Q4
- Roper Technologies downgraded to Hold from Buy at Melius Research
